Home » Stocks » BCLI

Brainstorm Cell Therapeutics Inc. (BCLI)

Stock Price: $3.52 USD -0.05 (-1.40%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $3.35 -0.17 (-4.83%) Jul 29, 7:18 PM
Market Cap 128.93M
Revenue (ttm) n/a
Net Income (ttm) -30.36M
Shares Out 35.79M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.52
Previous Close $3.57
Change ($) -0.05
Change (%) -1.40%
Day's Open 3.60
Day's Range 3.46 - 3.63
Day's Volume 120,295
52-Week Range 2.92 - 17.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received G...

2 days ago - PRNewsWire

NEW YORK, July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will h...

3 days ago - PRNewsWire

NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant an...

1 month ago - PRNewsWire

NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a p...

2 months ago - PRNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for...

3 months ago - PRNewsWire

NEW YORK, April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will...

3 months ago - PRNewsWire

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has reported topline Phase 2 data evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given two months apart, as a treatment for pro...

4 months ago - Benzinga

NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data f...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). S...

4 months ago - Newsfile Corp

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors a...

4 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI...

5 months ago - Business Wire

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors a...

5 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the ...

5 months ago - Business Wire

The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently provide the ...

5 months ago - Benzinga

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recentl...

5 months ago - PRNewsWire

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical com...

Other stocks mentioned: INFI, ORTX, VIVO
5 months ago - Benzinga

The company isn't giving up on a promising pipeline drug.

5 months ago - The Motley Fool

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for t...

5 months ago - PRNewsWire

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-review...

6 months ago - PRNewsWire

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter f...

7 months ago - PRNewsWire

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing...

7 months ago - PRNewsWire

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment ...

8 months ago - Insider Monkey

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that results fr...

8 months ago - PRNewsWire

Brainstorm Cell Therapeutics (BCLI) news for Tuesday has BCLI stock taking a beating following results from its ALS study. The post Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors t...

8 months ago - InvestorPlace

The company reported disappointing results from a pivotal clinical trial.

8 months ago - The Motley Fool

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results...

8 months ago - PRNewsWire

PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading devel...

9 months ago - PRNewsWire

Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for ...

9 months ago - PRNewsWire

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg,...

9 months ago - PRNewsWire

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative disease...

9 months ago - PRNewsWire

NEW YORK, Sept. 30, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of ...

9 months ago - PRNewsWire

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc.

10 months ago - PRNewsWire

Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4 Company plans to further strengthen its regulatory expertise and capabi...

10 months ago - GlobeNewsWire

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

11 months ago - PRNewsWire

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

11 months ago - PRNewsWire

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

11 months ago - PRNewsWire

Brainstorm Cell Therapeutics Inc (BCLI) CEO Chaim Lebovits on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model

1 year ago - GlobeNewsWire

NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader ...

1 year ago - PRNewsWire

NEW YORK, July 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final parti...

1 year ago - PRNewsWire

NEW YORK, June 24, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical ...

1 year ago - PRNewsWire

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it h...

1 year ago - GlobeNewsWire

NEW YORK, June 11, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits,...

1 year ago - PRNewsWire

WASHINGTON, June 9, 2020 /PRNewswire/ -- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI),...

1 year ago - PRNewsWire

NEW YORK, June 3, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, ...

1 year ago - PRNewsWire

NEW YORK, June 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the...

1 year ago - PRNewsWire

NEW YORK, May 27, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Li...

1 year ago - PRNewsWire

BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseas...

1 year ago - GlobeNewsWire

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is ... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Chaim Lebovits
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
BCLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BCLI stock is "Hold" and the 12-month stock price forecast is 11.50.

Price Target
$11.50
Analyst Consensus: Hold